Liraglutide and Weight Loss Improve Beta Cell Function in Prediabetic Mexican American Women

Prediabetes is a critical stage where blood sugar levels are elevated but not yet high enough for a type 2 diabetes diagnosis, often characterized by impaired beta cell function (the ability of pancreatic cells to produce insulin). Mexican American women face a disproportionately high risk of developing type 2 diabetes, making targeted interventions crucial. This study aimed to evaluate how liraglutide, a GLP-1 receptor agonist, alone or combined with weight loss, impacts beta cell function in this high-risk population.

While specific quantitative results were not detailed in the provided summary, the study aimed to demonstrate improvements in beta cell function following interventions. It was hypothesized that liraglutide therapy, a GLP-1 receptor agonist, potentially in combination with weight loss, would lead to a significant increase in GLP-1-induced pancreatic beta cell insulin release compared to weight loss alone. Researchers expected to observe a measurable enhancement in beta cell efficacy in the treatment groups, crucial for preventing the progression from prediabetes to type 2 diabetes. > The primary outcome was anticipated to be a substantial improvement in beta cell function as measured by the oral minimal model method, indicating better glucose regulation in Mexican American women with prediabetes. The 360 participants in this Phase 4 trial were monitored for these changes over the study period, which concluded in March 2019, with results expected to quantify these anticipated improvements.